A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Smoking

Treatments: Drug: taranabant

Study type: Interventional

Funder types: Industry

Identifiers

NCT00109135

MK-0364-007

0364-007

2005_012

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and tolerability of an investigational drug that may help individuals to stop smoking.

Enrollment: 300 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Smoking greater than/equal to 10 cigarettes/day for at least 1 year
• Laboratory tests that meet the criteria of the study
• In overall good health as determined by the investigator

Exclusion criteria

• Psychiatric diagnoses
• Certain cancers
• Patients who use nicotine replacement therapy
• Patients on a diet regimen

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind